Titration Dilemma: Mixed Apnea Emergence During CPAP Titration
A 63-year-old man with heart failure (LVEF 35%), atrial fibrillation, and BMI 36 undergoes in-lab CPAP titration for severe OSA (AHI 71, mostly obstructive, with central apnea index 4 at baseline). At 8 cm H2O his obstructive events resolve, but at 10-12 cm H2O he develops frequent central apneas with desaturations to 82%, and the central apnea index rises to 28/hour with a Cheyne-Stokes pattern. He is asymptomatic during the night but his oxygen saturation is labile. The technologist asks whether to keep increasing pressure to eliminate all events.
1. What is the physiology behind the emergence of central apneas at higher PAP, and why should pressure not simply be increased further?
Read the worked answer
This is treatment-emergent central sleep apnea (complex sleep apnea), occurring in a patient with HFrEF and AF - a phenotype predisposed to central apnea (Cheyne-Stokes respiration). Mechanisms:
- PAP hyperventilation: positive pressure can increase tidal volume and wash out CO2, dropping PaCO2 below the apneic threshold, especially in patients with a narrow CO2 reserve (heart failure, low LVEF).
- Loop gain and delay: in heart failure, prolonged circulation time plus high controller gain produces cyclic breathing (Cheyne-Stokes), and PAP can unmask or worsen this.
- Arousal threshold and sleep stage effects: central events often emerge in NREM and can vary with stage.
Increasing pressure further is the wrong move: it can worsen central events and hypoxemia by driving CO2 lower, and it does not address the underlying loop gain. The goal is to find the pressure that controls obstructive events while minimizing central events, not to chase a zero AHI.
2. What titration and device strategies would you use, and what follow-up would you arrange?
Read the worked answer
Titration strategy:
- Back-titrate to the pressure that abolished obstructive events with the fewest central events (here, near 8 cm H2O), and accept a residual central index if oxygenation is acceptable.
- Consider BPAP with a backup rate (adaptive servo-ventilation is generally avoided in HFrEF with LVEF ≤45% because of the SERVE-HF mortality signal). If central apnea persists and is clinically significant, options include BPAP with backup rate, or ASV only after cardiology discussion and outside the low-LVEF population.
- Optimize heart failure management with cardiology: guideline-directed medical therapy, volume status, and consideration of AF rate/rhythm management - improving cardiac function can reduce loop gain and central events.
- Oxygen or CO2-targeted approaches are not first-line but may be considered by a sleep specialist.
- Reassess after an acclimatization period: a substantial fraction of treatment-emergent central apnea resolves with continued PAP use, so repeat study after several weeks of adherence is reasonable before committing to advanced devices.
Follow-up:
- Repeat attended titration or a PAP download plus oximetry after a trial at the lower pressure.
- Coordinate with cardiology regarding LVEF and the ASV contraindication.
- Counsel the patient about adherence and symptoms; document the device choice rationale, especially the avoidance of ASV given LVEF 35%.